HRS-1893 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Phase I Trial on the Relative Bioavailability and Food Effect of HRS-1893 Tablets in Healthy Subjects (clinicaltrials.gov) - P1 | N=38 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Cardiomyopathy • Cardiovascular

A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure

A Trial of HRS-1893 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Atridia Pty Ltd. | Recruiting ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Nephrology • Renal Disease

A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P2 | N=300 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug (South China Morning Post) - "The deal gives Braveheart Bio exclusive worldwide rights to develop, manufacture and commercialise the drug...HRS-1893...outside mainland China, Hong Kong, Macau and Taiwan. Jiangsu Hengrui will receive an initial payment totalling US$75 million, which includes cash, Braveheart Bio shares and a near-term milestone payment of up to US$10 million."

Licensing / partnership • Obstructive Hypertrophic Cardiomyopathy

Safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-1893 in patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, placebo-controlled phase 1 trial (ESC-WCC 2025) - "Conclusion HRS-1893 demonstrated favourable safety and PK profiles. It rapidly and effectively reduced resting and Valsalva LVOT-G, while keeping LVEF within the safety limits, providing a novel treatment option for patients with obstruction HCM."

Clinical • P1 data • PK/PD data • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P3 | N=216 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Trial of HRS-1893 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Atridia Pty Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

A Trial of HRS-1893 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Atridia Pty Ltd.

New P1 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P3 | N=216 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P3 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P2 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Pharmacokinetic study of HRS-1893 tablets in subjects with mild and moderate renal insufficiency and healthy subjects (ChiCTR) - P1 | N=24 | Recruiting | Sponsor: Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital

New P1 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Nephrology • Renal Disease

A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P2 | N=42 | Active, not recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial primary completion date: Mar 2025 ➔ Nov 2024

Enrollment closed • Trial primary completion date • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Nephrology • Renal Disease

A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P2 | N=84 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P2 | N=84 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P2 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Non-obstructive Hypertrophic Cardiomyopathy

Safety and Pharmacokinetics Study of HRS-1893 Tablets in Healthy Subjects and Those With Impaired Kidney Function (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Nephrology • Renal Disease

A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P1 | N=76 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P2 | N=42 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P2 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy

HRS-1893-102: Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

HRS-1893-102: Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

HRS-1893-102: Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects (clinicaltrials.gov) - P1 | N=14 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects (clinicaltrials.gov) - P1 | N=14 | Not yet recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd.

New P1 trial • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy

A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy (clinicaltrials.gov) - P1 | N=106 | Recruiting | Sponsor: Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiomyopathy • Cardiovascular • Hypertrophic Cardiomyopathy • Obstructive Hypertrophic Cardiomyopathy